{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Imielinski M"],"funding":["NCI NIH HHS"],"pagination":["1582-6"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3973082"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["124(4)"],"pubmed_abstract":["Targeted cancer therapies often induce \"outlier\" responses in molecularly defined patient subsets. One patient with advanced-stage lung adenocarcinoma, who was treated with oral sorafenib, demonstrated a near-complete clinical and radiographic remission for 5 years. Whole-genome sequencing and RNA sequencing of primary tumor and normal samples from this patient identified a somatic mutation, ARAF S214C, present in the cancer genome and expressed at high levels. Additional mutations affecting this residue of ARAF and a nearby residue in the related kinase RAF1 were demonstrated across 1% of an independent cohort of lung adenocarcinoma cases. The ARAF mutations were shown to transform immortalized human airway epithelial cells in a sorafenib-sensitive manner. These results suggest that mutan"],"journal":["The Journal of clinical investigation"],"pubmed_title":["Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma."],"pmcid":["PMC3973082"],"funding_grant_id":["U10 CA180870","P30 CA016058","U10 CA180794","T32 CA009216","T32 CA9216-31","U01 CA114771","U10 CA180820","U24 CA114737","U10 CA021115","U01CA114771"],"pubmed_authors":["Amann J","Horn L","Carbone DP","Kaplan B","Schiller J","Villalona-Calero MA","Meyerson M","Greulich H","Imielinski M","Araujo L"],"additional_accession":[]},"is_claimable":false,"name":"Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.","description":"Targeted cancer therapies often induce \"outlier\" responses in molecularly defined patient subsets. One patient with advanced-stage lung adenocarcinoma, who was treated with oral sorafenib, demonstrated a near-complete clinical and radiographic remission for 5 years. Whole-genome sequencing and RNA sequencing of primary tumor and normal samples from this patient identified a somatic mutation, ARAF S214C, present in the cancer genome and expressed at high levels. Additional mutations affecting this residue of ARAF and a nearby residue in the related kinase RAF1 were demonstrated across 1% of an independent cohort of lung adenocarcinoma cases. The ARAF mutations were shown to transform immortalized human airway epithelial cells in a sorafenib-sensitive manner. These results suggest that mutan","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Apr","modification":"2025-04-20T02:45:58.774Z","creation":"2019-03-27T01:24:18Z"},"accession":"S-EPMC3973082","cross_references":{"pubmed":["24569458"],"doi":["10.1172/jci72763","10.1172/JCI72763"]}}